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Certain Viruses Cause Cancer, but Reprogrammed
Ones May Cure It
About a century ago, shortly after viruses were recognized,
occasional tumor regressions were documented after natural
infections. This observation established the idea of using viruses
to fight cancer [1]. Early virotherapy clinical trials based on
natural viruses were poorly controlled, but recent ones based on
modified viruses are subject to extensive monitoring of viral
replication, gene expression, and host immunity. Therapeutic
efficacy is being assessed by well-defined biological end points, and
can be improved [2]. For future clinical trials, more specific and
potent oncolytic viruses are being developed based on three
principles: targeting, shielding, and arming [3].
Box 1 lists several strategies currently utilized for each category of
modification; not all modifications are applicable to all viruses, but
interesting combinations of modifications can be applied to many
viruses to enhance therapy, as recently discussed [3]. We focus here
on the contribution of paramyxoviruses to the development of the
next generation of cancer therapeutics, and in particular on targeting
viral entry to cancer cells (Box 1, top two lines). We also bring
examples of how paramyxovirus envelopes can shield oncolytic
viruses from pre-existing antibodies, as well as target viruses of other
families, in particular retro- and lentiviruses. Finally, we present one
example of arming that enhances efficacy of virotherapy through its
direct integration into a chemotherapy regimen, locally amplifying its
effect. We note that modern virotherapy, while based on the creative
application of basic knowledge derived from the study of viruses, is
driven by the need for new alternatives for cancer treatment. Thus,
while work creating and validating the next generation of vectors
progresses, current clinical trials are based on vectors developed 5–10
years ago [4].
Targeting I: Paramyxoviruses Can Enter Cells
through Designated Receptors
Not all viruses can be readily targeted to enter cells through
designated receptors. Cell entry targeting of icosahedral viruses like
adenovirus is complicated by the multiple constraints of their capsid
symmetry: maintaining efficient assembly while modifying the capsid
proteins is a challenge, but some success has been reported based on
the display of short peptides [5]. On the other hand, targeting of
enveloped, non-icosahedral viruses has progressed more rapidly
utilizing large specificity domains, including single chain antibodies,
displayed on the envelope proteins.
From the beginning, the envelope of paramyxoviruses was
considered an attractive targeting substrate because receptor
attachment and fusion function are separated on two proteins. In
contrast, a single protein in retroviruses performs both functions,
which has complicated retargeting strategies. The two-protein entry
system of paramyxoviruses is also simpler than those of large DNA
viruses that use several proteins. Among paramyxoviruses, which are
non-segmented negative-strand RNA viruses with a helical capsid,
targeting of the measles virus (MV) envelope is the most advanced.
MVenterscellsbyenvelope–membranefusionatthecellsurfaceat
neutral pH. Two glycoproteins mediate this process: the hemagglu-
tinin (H) and fusion (F) proteins (Figure 1). The H-protein binds to
receptors, while the F-protein mediates fusion of the viral and cellular
membranes. H naturally interacts with at least three different
receptors. The wild-type virus primarily uses the signaling lympho-
cyte activation molecule (SLAM, CD150) expressed on certain
immune cells, while the vaccine strain has gained the ability to also
use the ubiquitous membrane cofactor protein (MCP, CD46), a
regulator of complement activation. Additionally, MV infects airway
and bladder epithelia through an as yet unidentified receptor
(epithelial cell receptor, EpR). The footprints of the three receptors
on H have been characterized (Figure 1) [6], and it was shown a
decade ago that MV attachment and cell entry can be readily
targeted to designated receptors by adding specificity determinants to
the H-protein carboxyl-terminus [7]. It was then demonstrated that
many larger specificity determinants, including single chain antibod-
ies, can be used to target MV entry [6]. These specificity
determinants are connected to the H-protein through a flexible
linker and are likely displayed on top of the H-protein head, as F and
H have tight lateral interactions.
For cancer treatment, specific receptors were chosen among the
targets of approved cancer therapeutics: for example, the
lymphoma therapeutic antibody Rituximab targets the B-lympho-
cyte marker CD20. Thus, a CD20-targeted MV was generated
and shown to prolong survival of immunodeficient mice in a
lymphoma model based on CD20-expressing B-cell xenografts [8].
What was initially missing was de-targeting from the natural
receptors CD46 and SLAM, but once the key residues of MV H
supporting entry through these receptors were mapped and
mutated [9], MV with fully retargeted entry were produced and
their efficacy confirmed in pre-clinical trials [10]. The single chain
antibody-based MV targeting system is versatile: many retargeted
MV have been generated and shown to be effective in different
animal models of oncolysis [3].
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Activated through Cancer-Specific Proteases
In situ activation through cancer-specific proteases is a second
targeting layer that can be applied to paramyxoviral envelopes. This
concept is based on the modification of the F-protein, which requires
protease cleavage for activation, and was developed for both Sendai
virus and MV [11,12]. Cleavage of the respective F-proteins was
made dependent on a matrix metalloprotease, MMP-2, which
recognizes and cleaves a specific hexapeptide sequence. MMPs are
zinc-dependent endopeptidases that promote tumor progression by
cleaving the extracellular matrix, and are up-regulated in almost
every type of human cancer [13]. A recombinant virus (MV-MMP)
wasgenerated witha variant of the hexapeptiderecognized byMMP-
2 appropriately engineered into the F-protein, and was unable to
propagate or produce a cytopathic effect unless it was added to cells
expressing MMP-2. In mice, MV-MMP retained full oncolytic
activity when inoculated into MMP-positive subcutaneous cancers,
but unlike wild-type MV, MV-MMP did not infect and kill
susceptible mice after intracranial inoculation, illustrating the
enhanced safety of the virus [12].
This retargeting strategy, based either on MMP or other
proteases [14], can be adapted to restrict cellular entry of other
enveloped viruses that have protease-activated F-proteins. Viruses
with such proteins currently in cancer clinical trials include herpes
simplex (HSV) among the enveloped DNA viruses, and Newcastle
disease virus among the paramyxoviruses.
Fitting Targeted Envelopes on Capsids of Other
Viruses; Shielding MV-Based Oncolytics
Entry retargeting of other enveloped viruses, especially retro-
and lentiviral vectors, has proven difficult. To address this
challenge, MV glycoproteins were incorporated into lentiviral
vectors [15]. To sustain efficient incorporation of the MV
glycoproteins in these vectors, it was necessary to precisely trim
their respective cytoplasmic tails. HIV nucleocapsids pseudotyped
with the CD20-targeted MV glycoproteins could deliver a reporter
gene with great specificity and efficiency to CD20-expressing
primary human lymphocytes. This work is important because it
proves that the versatile MV envelope-based targeting system can
be transferred to the most advanced vectors used for correction of
genetic diseases [16].
While MV glycoprotein-retargeted lentiviral vectors have the
potential to reduce off-target integration of vector genomes in
trials based on ex vivo gene transfer, the prevalence of MV
neutralizing antibodies in human sera interferes with the systemic
delivery of these vectors. To circumvent neutralization issues, the
use of envelopes from non-human paramyxoviruses have been
considered. In particular, the envelope glycoproteins of Tupaia
paramyxovirus [17] and canine distemper virus, which can be
retargeted with single chain antibodies, have minimal if any
cross-reactivity with human sera (K. C. Yaiw, J. Lampe, G.
Ungerechts, R. Cattaneo, unpublished data). Once these
retargeted paramyxoviral envelopes are properly fitted onto
lentiviral vectors, such vectors could be inoculated systemically
for targeted gene transfer.
This shielding principle can also be applied to MV vectors: the
envelopes of non-human paramyxoviruses can be fitted onto MV
nucleocapsids to produce chimeric viruses that evade pre-
existing MV immunity, at least temporarily. We refer to a
recent review [3] for discussion of this and other shielding
principles that are currently being tested in pre-clinical and
clinical trials of oncolytic viruses (see also Box 1, shielding). In
short, polymers have been used to shield icosahedral viruses, in
particular adenovirus, while cell carrier shielding has been used
for many viruses, including MV. It is also revealing that several
current clinical trials focus on cancer types that can be treated
locally, like glioma in the brain or ovarian carcinoma in the
peritoneum, avoiding intravenous injections and immediate
neutralization. Finally, host immunosuppression with cyclophos-
phamide prior to virus administration enhances oncolytic
efficacy, likely by suppressing host innate and adaptive immunity
and temporarily favoring virus replication.
Arming: Reprogrammed Viruses Enhancing
Established Cancer Therapeutics
A fundamental paradigm of cancer therapy is that no single
drug or treatment will cure cancer. Therefore, most therapeutic
regimens for cancer are based on combinations of drugs,
radiation, and surgery to maximize patient survival. As oncolytic
viruses have so far provided incomplete cancer cures, the field has
moved towards combining these viruses with traditional thera-
pies. The most promising new avenue of experimentation is to
integrate different components of current cancer therapy
regimens with reprogrammed viruses expressing specific trans-
genes [18].
One example of this integrative approach is based on an armed
and targeted MV that may improve the efficacy of the FCR
(fludarabine, cyclophosphamide, Rituxan) regimen. This regimen
is the front-line treatment for select non-Hodgkin lymphoma, and
is based on cycles of treatment with fludarabine phosphate,
cyclophosphamide/cytoxan, and the anti-CD20 antibody Ri-
tuxan. As an alternative to Rituxan, a CD20-targeted MV was
considered. This vector was also armed with the prodrug
convertase purine nucleotide phosphorylase, which converts
fludarabine phosphate to a highly diffusible substance that is
capable of efficiently killing bystander cells. The CD20-targeted
and convertase-armed MV was shown to synergize with
Box 1. Virus Reprogramming: Three
Principles, Many Combinatorial Options
TARGETING
N Entry – I: receptors
N Entry – II: particle activation (proteases)
N Post-entry – I: transcription and replication (promoters)
N Post-entry – II: selective replication (cancer cell defects)
SHIELDING
N Envelope exchange (serotypes, or related viruses)
N Chemical (polymer coating)
N Biological (infected cell carriers)
N Local treatment (intratumoral application)
N Temporary immunosuppression (cyclophosphamide)
ARMING
N Prodrug convertases (e.g., PNP/fludarabine)
N Iodine symporter
N Pro-apoptotic proteins
N Selective disarming in normal cells (interferons, GM-CSF)
(Examples discussed in the text are bolded.)
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tion in a mantle cell lymphoma xenograft model [19]. Recently,
precise timing of cyclophosphamide, virus, and fludarabine
administration was shown to increase the window of therapeutic
opportunity [20]. An alternative approach foresees arming
CD20-targeted MV with the thyroidal natrium iodide symporter
(NIS) gene, enhancing bystander effect by exploiting infected
tumor cells to efficiently and locally concentrate radioiodine [21].
Again, this strategy improves on current clinical trials of non-
Hodgkin lymphoma based on the I-131 labeled Tositumomab
monoclonal antibody.
In conclusion, the first oncolytic virus approved as a cancer
drug has been administered to thousand of patients in China
[22], multiple viruses with improved oncolytic properties are
currently being tested in well-controlled clinical trials, and the
next generation of targeted viruses capable of integrating
chemo- and radiotherapies is approaching clinical testing.
Virus-based cancer therapies are on the horizon and rapidly
approaching [23].
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